NEW YORK (GenomeWeb News) — GenOway will supply “a leading” but undisclosed US pharmaceutical company with its genetically modified mouse lines in exchange for up to $2 million, the firm said yesterday.
 
GenOway makes a line of genetically modified mouse and rat lines, and uses knowledge in transgenic technologies including pronuclear microinjection, knock-out, knock-in, knock-down, point mutation, in vivo drug screening, drug efficacy, and safety testing.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.